The Leukemia & Lymphoma Society Launches First Clinical Trial Specifically for Blood Cancer Patients With COVID-19
September 10, 2020
September 10, 2020
RYE BROOK, New York, Sept. 10 (TNSPPX) -- The Leukemia and Lymphoma Society issued the following news release on Sept. 9:
With studies showing between 30-60% of blood cancer patients at risk of death if infected with the COVID-19 virus compared to patients who are cancer-free, The Leukemia & Lymphoma Society (LLS) announced today it is launching the first clinical trial dedicated solely to this most vulnerable population.
This trial (LLS Protocol Number: BAML-16-001 . . .
With studies showing between 30-60% of blood cancer patients at risk of death if infected with the COVID-19 virus compared to patients who are cancer-free, The Leukemia & Lymphoma Society (LLS) announced today it is launching the first clinical trial dedicated solely to this most vulnerable population.
This trial (LLS Protocol Number: BAML-16-001 . . .